entertainment -WSS

entertainment

author：fashion 2025-09-30 17:28:55 - browse：81

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Criminal prosecution for violating HIPAA: an emerging threat

Wikipedia

WSS

How dance can help health care workers heal from trauma

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Readers respond to H5N1 and livestock movements, and more

Big Tobacco's 'harm reduction': Is it for real, or a sham?

States increasingly look to regulate hospital facility fees

HIV vaccine remains elusive. Immunologists keep trying new ideas

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

After affirmative action ruling, medical educators look to 'holistic review'

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Heart attack and stroke risk calculators need revising

Data integrity in scientific journals requires "effort" by publishers, institutions

Dobbs anniversary: the lost opportunity of abortion as health care

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Novavax promises a turnaround & Lilly roils the obesity market

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

The high cost of giving birth even with insurance

Anxious about a speech? A startup wants you to pop a minty cardiac drug

explore

Wearables generate powerful data but its not useful to doctors, yet

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Couple fighting to bring baby home from Mexico are finally reunited

TikTok cracks down on users posting about weight loss drugs

Bird flu: Don't repeat Covid's 'health versus the economy' framing

TikTok cracks down on users posting about weight loss drugs

Wikipedia

Wikipedia

hotspot

focus